Stock Analysis on Net
Stock Analysis on Net

Edwards Lifesciences Corp. (NYSE:EW)

This company has been moved to the archive! The financial data has not been updated since February 14, 2022.

Adjustments to Financial Statements

Microsoft Excel

Adjustments to Current Assets

Edwards Lifesciences Corp., adjusted current assets

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Current assets 3,180,700 3,091,000 2,984,000 2,286,900 2,532,100
Adjustments
Add: Allowance for doubtful accounts 9,300 9,600 8,700 8,900 8,500
After Adjustment
Adjusted current assets 3,190,000 3,100,600 2,992,700 2,295,800 2,540,600

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).


The financial trajectory of current assets over the five-year period ending December 31, 2021, is characterized by an initial contraction followed by a sustained period of growth. Both the reported current assets and the adjusted current assets move in synchronization, indicating a consistent relationship between the two metrics.

Current Asset Trend Analysis
A decrease in current assets is observed between 2017 and 2018, where values fell from 2,532,100 to 2,286,900. This downward movement was reversed in 2019, with a substantial increase to 2,984,000. The upward trend persisted through 2020 and 2021, culminating in a peak value of 3,180,700.
Adjustment Delta Evaluation
Adjusted current assets consistently exceed reported current assets in every period analyzed. The absolute difference between these two figures remains stable, ranging from a minimum of 8,500 in 2017 to a maximum of 9,600 in 2020. This indicates a systemic and predictable adjustment applied to the current asset base.
Materiality of Adjustments
The adjustments are immaterial in relation to the total asset volume. Throughout the observed period, the variance between reported and adjusted current assets represents a fraction of 1% of the total assets, suggesting that these adjustments do not fundamentally alter the interpretation of the company's liquidity position or short-term financial health.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Total Assets

Edwards Lifesciences Corp., adjusted total assets

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Total assets 8,502,600 7,237,100 6,488,100 5,323,700 5,695,800
Adjustments
Add: Operating lease right-of-use asset (before adoption of FASB Topic 842)1 — — — 82,604 67,539
Add: Allowance for doubtful accounts 9,300 9,600 8,700 8,900 8,500
Less: Deferred tax assets2 246,700 230,900 172,200 174,000 213,600
After Adjustment
Adjusted total assets 8,265,200 7,015,800 6,324,600 5,241,204 5,558,239

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Operating lease right-of-use asset (before adoption of FASB Topic 842). See details »

2 Deferred tax assets. See details »


An analysis of the asset base reveals a consistent growth trajectory from 2018 through 2021, following a slight contraction in the initial period. Total assets increased from 5,695,800 thousand US$ in 2017 to 8,502,600 thousand US$ by the end of 2021, representing an overall expansion of approximately 49.3% over the five-year period.

Asset Growth Trends
A momentary decline in total assets was observed between 2017 and 2018, where values fell from 5,695,800 thousand US$ to 5,323,700 thousand US$. However, this was followed by three consecutive years of robust growth, with the most significant annual increase occurring between 2020 and 2021, adding 1,265,500 thousand US$ to the total asset base.
Correlation Between Total and Adjusted Assets
Adjusted total assets mirrored the movements of total assets throughout the observed period. The synchronized fluctuations indicate that the factors necessitating the adjustments remained proportional to the overall growth of the company's balance sheet.
Analysis of Asset Adjustments
The variance between total assets and adjusted total assets remained relatively narrow, typically ranging between 1.5% and 3.1% of the total value. The absolute difference grew from 137,561 thousand US$ in 2017 to 237,400 thousand US$ in 2021, suggesting that while the scale of adjustments increased in absolute terms, they did not fundamentally alter the financial positioning or the growth profile of the asset base.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Total Liabilities

Edwards Lifesciences Corp., adjusted total liabilities

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Total liabilities 2,666,700 2,662,800 2,339,800 2,183,300 2,739,600
Adjustments
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — 82,604 67,539
Less: Deferred tax liabilities2 24,600 28,100 36,800 9,000 27,600
After Adjustment
Adjusted total liabilities 2,642,100 2,634,700 2,303,000 2,256,904 2,779,539

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Deferred tax liabilities. See details »


The financial trajectory of total liabilities between 2017 and 2021 is characterized by an initial significant contraction followed by a steady recovery and eventual stabilization. Total liabilities decreased from 2,739,600 thousand US dollars in 2017 to a period low of 2,183,300 thousand US dollars in 2018, representing a reduction of approximately 20.3%. Subsequently, a consistent upward trend was observed from 2019 through 2021, with the balance returning to 2,666,700 thousand US dollars by the end of the period.

Liability Trend Analysis
A V-shaped recovery pattern is evident in the reported liabilities. After the sharp decline in 2018, liabilities rose by 7.2% in 2019 and 13.7% in 2020, before reaching a plateau in 2021 where the increase was marginal at 0.15%.
Adjustment Variance Patterns
The relationship between total liabilities and adjusted total liabilities shifted mid-period. In 2017 and 2018, adjusted liabilities were higher than reported liabilities, with the largest positive variance occurring in 2018 at 73,604 thousand US dollars. Conversely, from 2019 to 2021, adjusted liabilities were consistently lower than the reported figures, indicating a reversal in the nature of the adjustments applied.
Convergence of Values
By the 2021 fiscal year, the gap between reported and adjusted liabilities narrowed to 24,600 thousand US dollars. This suggests a higher degree of alignment between the standard reporting and the adjusted financial metrics toward the end of the analyzed five-year window.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Stockholders’ Equity

Edwards Lifesciences Corp., adjusted stockholders’ equity

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Stockholders’ equity 5,835,900 4,574,300 4,148,300 3,140,400 2,956,200
Adjustments
Less: Net deferred tax assets (liabilities)1 222,100 202,800 135,400 165,000 186,000
Add: Allowance for doubtful accounts 9,300 9,600 8,700 8,900 8,500
After Adjustment
Adjusted stockholders’ equity 5,623,100 4,381,100 4,021,600 2,984,300 2,778,700

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Net deferred tax assets (liabilities). See details »


A consistent upward trajectory in both total and adjusted stockholders' equity is observed over the five-year period ending December 31, 2021. Total stockholders' equity grew from US$ 2,956,200 thousand in 2017 to US$ 5,835,900 thousand in 2021, representing a substantial increase in the company's net asset position. Adjusted stockholders' equity mirrored this growth, rising from US$ 2,778,700 thousand to US$ 5,623,100 thousand over the same timeframe.

Growth Velocity and Volatility
The expansion of equity was not linear, with the most significant accelerations occurring in 2019 and 2021. Between 2018 and 2019, stockholders' equity increased by approximately 32.1%, and between 2020 and 2021, it grew by 27.6%. Moderate growth was observed in 2018 and 2020, indicating periods of relative stabilization amidst the broader growth trend.
Analysis of Equity Adjustments
A persistent gap exists between the reported stockholders' equity and the adjusted stockholders' equity. In 2017, the adjustment amount was US$ 177,500 thousand, or approximately 6.0% of the total equity. By 2021, the adjustment amount increased to US$ 212,800 thousand, although it represented a smaller proportion of the total equity at approximately 3.6%.
Correlation Between Metric Sets
There is a near-perfect positive correlation between the reported and adjusted equity figures. Both metrics moved in tandem across all reporting periods, suggesting that the factors necessitating the adjustments were not volatile enough to decouple the adjusted figures from the overall trend of the total equity base.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Capitalization Table

Edwards Lifesciences Corp., adjusted capitalization table

US$ in thousands

Microsoft Excel
Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Short-term debt — — — — 598,000
Long-term debt 595,700 595,000 594,400 593,800 438,400
Total reported debt 595,700 595,000 594,400 593,800 1,036,400
Stockholders’ equity 5,835,900 4,574,300 4,148,300 3,140,400 2,956,200
Total reported capital 6,431,600 5,169,300 4,742,700 3,734,200 3,992,600
Adjustments to Debt
Add: Operating lease liability (before adoption of FASB Topic 842)1 — — — 82,604 67,539
Add: Operating lease liabilities, current portion2 25,500 27,200 25,500 — —
Add: Operating lease liabilities, long-term portion3 69,100 72,700 58,900 — —
Adjusted total debt 690,300 694,900 678,800 676,404 1,103,939
Adjustments to Equity
Less: Net deferred tax assets (liabilities)4 222,100 202,800 135,400 165,000 186,000
Add: Allowance for doubtful accounts 9,300 9,600 8,700 8,900 8,500
Adjusted stockholders’ equity 5,623,100 4,381,100 4,021,600 2,984,300 2,778,700
After Adjustment
Adjusted total capital 6,313,400 5,076,000 4,700,400 3,660,704 3,882,639

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Operating lease liability (before adoption of FASB Topic 842). See details »

2 Operating lease liabilities, current portion. See details »

3 Operating lease liabilities, long-term portion. See details »

4 Net deferred tax assets (liabilities). See details »


The financial trajectory between 2017 and 2021 is characterized by a significant initial reduction in leverage followed by a period of steady equity expansion. The overall capital structure has shifted toward a more equity-heavy composition, enhancing the long-term solvency profile of the organization.

Debt Profile and Adjustments
A substantial contraction in reported debt occurred between 2017 and 2018, where levels decreased from 1,036,400 thousand USD to 593,800 thousand USD. Following this decline, reported debt remained nearly stagnant through 2021. Adjusted debt figures were consistently higher than reported figures throughout the period, indicating a systematic adjustment for additional liabilities. By December 31, 2021, adjusted debt stood at 690,300 thousand USD, maintaining a similar proportional variance to reported debt as seen in previous years.
Equity Growth Trends
Stockholders' equity exhibited consistent and robust growth, increasing from 2,956,200 thousand USD in 2017 to 5,835,900 thousand USD in 2021. Adjusted stockholders' equity followed a nearly identical growth curve but remained systematically lower than the reported figures. This consistent downward adjustment suggests the removal of specific equity components to arrive at a more conservative capital valuation.
Total Capitalization Dynamics
Total reported capital experienced a slight dip in 2018 due to the reduction in debt but grew aggressively thereafter, reaching 6,431,600 thousand USD by the end of 2021. Adjusted total capital mirrored this trend, growing from 3,882,639 thousand USD in 2017 to 6,313,400 thousand USD in 2021. The growth in total capital is primarily attributed to the expansion of the equity base rather than the accumulation of debt, reflecting a strengthened financial position.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?


Adjustments to Reported Income

Edwards Lifesciences Corp., adjusted net income

US$ in thousands

Microsoft Excel
12 months ended: Dec 31, 2021 Dec 31, 2020 Dec 31, 2019 Dec 31, 2018 Dec 31, 2017
As Reported
Net income 1,503,100 823,400 1,046,900 722,200 583,600
Adjustments
Add: Deferred income tax expense (benefit)1 (44,000) (52,200) 10,500 (21,200) 27,100
Add: Increase (decrease) in allowance for doubtful accounts (300) 900 (200) 400 (500)
Add: Other comprehensive income (loss), net of tax 3,400 (5,100) (17,500) 2,000 65,700
After Adjustment
Adjusted net income 1,462,200 767,000 1,039,700 703,400 675,900

Based on: 10-K (reporting date: 2021-12-31), 10-K (reporting date: 2020-12-31), 10-K (reporting date: 2019-12-31), 10-K (reporting date: 2018-12-31), 10-K (reporting date: 2017-12-31).

1 Deferred income tax expense (benefit). See details »


The financial performance between 2017 and 2021 is characterized by substantial long-term growth in profitability, interrupted by a contraction in 2020. Both reported and adjusted net income figures demonstrate a strong recovery and peak performance in 2021, indicating a robust capacity for earnings expansion over the five-year period.

Net Income Trajectory
Reported net income exhibited a strong upward trend, increasing from 583,600 thousand US$ in 2017 to 1,503,100 thousand US$ in 2021. While growth was consistent through 2019, a decline to 823,400 thousand US$ occurred in 2020. This was followed by a sharp recovery in 2021, representing a year-over-year increase of approximately 82.6%.
Adjusted Net Income Trends
Adjusted net income mirrors the trajectory of reported net income, rising from 675,900 thousand US$ in 2017 to 1,462,200 thousand US$ in 2021. Similar to the reported figures, a contraction was noted in 2020, where values fell to 767,000 thousand US$, before rebounding significantly in the final year of the period.
Analysis of Income Adjustments
A shift in the relationship between reported and adjusted figures is observable. In 2017, adjusted net income was higher than reported net income by 92,300 thousand US$, suggesting the exclusion of significant non-recurring expenses. Conversely, from 2018 through 2021, reported net income consistently exceeded adjusted net income. The variance peaked in 2020, where reported net income was 56,400 thousand US$ higher than the adjusted figure, indicating a change in the composition of items being adjusted out of the earnings reports.

AI Ask an analyst for more

Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.

How can I help you?